87 related articles for article (PubMed ID: 26459389)
1. EPI-X4, a novel endogenous antagonist of CXCR4.
Buske C; Kirchhoff F; Münch J
Oncotarget; 2015 Nov; 6(34):35137-8. PubMed ID: 26459389
[No Abstract] [Full Text] [Related]
2. Discovery and characterization of an endogenous CXCR4 antagonist.
Zirafi O; Kim KA; Ständker L; Mohr KB; Sauter D; Heigele A; Kluge SF; Wiercinska E; Chudziak D; Richter R; Moepps B; Gierschik P; Vas V; Geiger H; Lamla M; Weil T; Burster T; Zgraja A; Daubeuf F; Frossard N; Hachet-Haas M; Heunisch F; Reichetzeder C; Galzi JL; Pérez-Castells J; Canales-Mayordomo A; Jiménez-Barbero J; Giménez-Gallego G; Schneider M; Shorter J; Telenti A; Hocher B; Forssmann WG; Bonig H; Kirchhoff F; Münch J
Cell Rep; 2015 May; 11(5):737-47. PubMed ID: 25921529
[TBL] [Abstract][Full Text] [Related]
3. Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations.
Gilg A; Harms M; Olari LR; Urbanowitz AK; Bonig H; Münch J
J Transl Med; 2021 May; 19(1):190. PubMed ID: 33941197
[TBL] [Abstract][Full Text] [Related]
4. Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists.
Sokkar P; Harms M; Stürzel C; Gilg A; Kizilsavas G; Raasholm M; Preising N; Wagner M; Kirchhoff F; Ständker L; Weidinger G; Mayer B; Münch J; Sanchez-Garcia E
Commun Biol; 2021 Sep; 4(1):1113. PubMed ID: 34552197
[TBL] [Abstract][Full Text] [Related]
5. Advanced EPI-X4 Derivatives Covalently Bind Human Serum Albumin Resulting in Prolonged Plasma Stability.
Rodríguez-Alfonso A; Heck A; Ruiz-Blanco YB; Gilg A; Ständker L; Kuan SL; Weil T; Sanchez-Garcia E; Wiese S; Münch J; Harms M
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499357
[TBL] [Abstract][Full Text] [Related]
6. Proteolytic processing of human serum albumin generates EPI-X4, an endogenous antagonist of CXCR4.
Zirafi O; Hermann PC; Münch J
J Leukoc Biol; 2016 Jun; 99(6):863-8. PubMed ID: 26965637
[TBL] [Abstract][Full Text] [Related]
7. Conformational States of the CXCR4 Inhibitor Peptide EPI-X4-A Theoretical Analysis.
Jung CK; Münch J; Jacob T
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003419
[TBL] [Abstract][Full Text] [Related]
8. An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation.
Harms M; Habib MMW; Nemska S; Nicolò A; Gilg A; Preising N; Sokkar P; Carmignani S; Raasholm M; Weidinger G; Kizilsavas G; Wagner M; Ständker L; Abadi AH; Jumaa H; Kirchhoff F; Frossard N; Sanchez-Garcia E; Münch J
Acta Pharm Sin B; 2021 Sep; 11(9):2694-2708. PubMed ID: 34589390
[TBL] [Abstract][Full Text] [Related]
9. Development of N-Terminally Modified Variants of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability.
Harms M; Fabech Hansson R; Gilg A; Almeida-Hernández Y; Löffler J; Rodríguez-Alfonso A; Habib MMW; Albers D; Ahmed NS; Abadi AH; Winter G; Rasche V; Beer AJ; Weidinger G; Preising N; Ständker L; Wiese S; Sanchez-Garcia E; Zelikin AN; Münch J
J Med Chem; 2023 Nov; 66(22):15189-15204. PubMed ID: 37940118
[TBL] [Abstract][Full Text] [Related]
10. Neutralising properties of peptides derived from CXCR4 extracellular loops towards CXCL12 binding and HIV-1 infection.
Chevigné A; Fievez V; Szpakowska M; Fischer A; Counson M; Plesséria JM; Schmit JC; Deroo S
Biochim Biophys Acta; 2014 May; 1843(5):1031-41. PubMed ID: 24480462
[TBL] [Abstract][Full Text] [Related]
11. Peptide-lead CXCR4 antagonists with high anti-HIV activity.
Fujii N; Tamamura H
Curr Opin Investig Drugs; 2001 Sep; 2(9):1198-202. PubMed ID: 11717804
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
[TBL] [Abstract][Full Text] [Related]
13. Peptide and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4).
Oishi S; Fujii N
Org Biomol Chem; 2012 Aug; 10(30):5720-31. PubMed ID: 22517031
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-4-transgenic hu-PBL-SCID mice: a model for the screening of antiviral drugs and immunotherapeutic agents against X4 HIV-1 viruses.
Okuma K; Tanaka R; Ogura T; Ito M; Kumakura S; Yanaka M; Nishizawa M; Sugiura W; Yamamoto N; Tanaka Y
J Infect Dis; 2008 Jan; 197(1):134-41. PubMed ID: 18171296
[TBL] [Abstract][Full Text] [Related]
15. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D
Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832
[TBL] [Abstract][Full Text] [Related]
16. Suppression of multiclade R5 and X4 human immunodeficiency virus type-1 infections by a coreceptor-based anti-HIV strategy.
Nakayama D; Misumi S; Mukai R; Tachibana K; Umeda M; Shibata H; Takamune N; Shoji S
J Biochem; 2005 Nov; 138(5):571-82. PubMed ID: 16272569
[TBL] [Abstract][Full Text] [Related]
17. Ligand selectivity of a synthetic CXCR4 mimetic peptide.
Groß A; Brox R; Damm D; Tschammer N; Schmidt B; Eichler J
Bioorg Med Chem; 2015 Jul; 23(14):4050-5. PubMed ID: 25801155
[TBL] [Abstract][Full Text] [Related]
18. Progress toward rationally designed small-molecule peptide and peptidomimetic CXCR4 antagonists.
Våbenø J; Haug BE; Rosenkilde MM
Future Med Chem; 2015; 7(10):1261-83. PubMed ID: 26144264
[TBL] [Abstract][Full Text] [Related]
19. Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages.
Ghaffari G; Tuttle DL; Briggs D; Burkhardt BR; Bhatt D; Andiman WA; Sleasman JW; Goodenow MM
J Virol; 2005 Nov; 79(21):13250-61. PubMed ID: 16227248
[TBL] [Abstract][Full Text] [Related]
20. A radiogallium-DOTA-based bivalent peptidic ligand targeting a chemokine receptor, CXCR4, for tumor imaging.
Sano K; Masuda R; Hisada H; Oishi S; Shimokawa K; Ono M; Fujii N; Saji H; Mukai T
Bioorg Med Chem Lett; 2014 Mar; 24(5):1386-8. PubMed ID: 24491461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]